Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier

G. Schernthaner, C. Lotan, E. Baltadzhieva-Trendafilova, J. Ceponis, M. Clodi, K. Ducena, E. Goncalvesova, C. Guja, M. Honka, A. Janež, N. Lalić, R. Lehmann, N. Nyolczas, P. Pauklin, A. Rynkiewicz, I. Sergienko, LS. Duvnjak,

. 2018 ; 17 (1) : 145. [pub] 20181121

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012126

Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be 'silent' or 'asymptomatic', but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anticipated that patients will receive an earlier diagnosis and appropriate and timely treatment. Given the availability of anti-diabetic medications that have been shown to concomitantly reduce CV risk and mortality, it is imperative to improve early identification and initiate treatment as soon as possible in order to enable as many patients with T2D as possible to benefit.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012126
003      
CZ-PrNML
005      
20190411094626.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12933-018-0788-7 $2 doi
035    __
$a (PubMed)30463621
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schernthaner, Guntram $u Medical University of Vienna, Vienna, Austria. guntram.schernthaner@meduniwien.ac.at.
245    10
$a Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier / $c G. Schernthaner, C. Lotan, E. Baltadzhieva-Trendafilova, J. Ceponis, M. Clodi, K. Ducena, E. Goncalvesova, C. Guja, M. Honka, A. Janež, N. Lalić, R. Lehmann, N. Nyolczas, P. Pauklin, A. Rynkiewicz, I. Sergienko, LS. Duvnjak,
520    9_
$a Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be 'silent' or 'asymptomatic', but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anticipated that patients will receive an earlier diagnosis and appropriate and timely treatment. Given the availability of anti-diabetic medications that have been shown to concomitantly reduce CV risk and mortality, it is imperative to improve early identification and initiate treatment as soon as possible in order to enable as many patients with T2D as possible to benefit.
650    _2
$a asymptomatické nemoci $7 D058070
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a krevní glukóza $x účinky léků $x metabolismus $7 D001786
650    _2
$a kardiovaskulární nemoci $x diagnóza $x mortalita $x terapie $7 D002318
650    _2
$a diabetes mellitus 2. typu $x krev $x diagnóza $x farmakoterapie $x mortalita $7 D003924
650    _2
$a časná diagnóza $7 D042241
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x terapeutické užití $7 D007004
650    _2
$a plošný screening $7 D008403
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lotan, Chaim $u Hadassah-Hebrew University Medical Center, Jerusalem, Israel. chaim.lotan@gmail.com.
700    1_
$a Baltadzhieva-Trendafilova, Elina $u National Cardiology Hospital, Sofia, Bulgaria.
700    1_
$a Ceponis, Jonas $u Institute of Endocrinology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
700    1_
$a Clodi, Martin $u Department of Internal Medicine, St. John Hospital, Linz, Austria.
700    1_
$a Ducena, Kristine $u Faculty of Internal Medicine, University of Latvia, Riga, Latvia.
700    1_
$a Goncalvesova, Eva $u Department of Heart Failure and Transplantation, National Institute of Cardiovascular Diseases, Bratislava, Slovak Republic.
700    1_
$a Guja, Cristian $u Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
700    1_
$a Honka, Marek $u Fakultní Nemocnice Ostrava, Poruba, Czech Republic.
700    1_
$a Janež, Andrej $u National Institute of Endocrinology and Diabetology, Lubochna, Slovakia.
700    1_
$a Lalić, Nebojša $u Clinic for Endocrinology, Diabetes and Metabolic Diseases, CCS, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
700    1_
$a Lehmann, Roger $u Division of Endocrinology and Diabetes of the University Hospital, Zurich, Switzerland.
700    1_
$a Nyolczas, Noémi $u Department of Cardiology, Hungarian Defence Forces-Medical Centre, Budapest, Hungary.
700    1_
$a Pauklin, Priit $u Department of Cardiology, Tartu University Hospital, Tartu, Estonia.
700    1_
$a Rynkiewicz, Andrzej $u Department of Cardiology and Cardiosurgery, School of Medicine, University of Warmia and Mazury, Olsztyn, Poland.
700    1_
$a Sergienko, Igor $u Russian Cardiology Research Complex, Moscow, Russia.
700    1_
$a Duvnjak, Lea Smirčić $u Department of Endocrinology and Metabolic Diseases, Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, School of Medicine, Endocrinology and Metabolic Diseases, University of Zagreb, Zagreb, Croatia.
773    0_
$w MED00008211 $t Cardiovascular diabetology $x 1475-2840 $g Roč. 17, č. 1 (2018), s. 145
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30463621 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190411094643 $b ABA008
999    __
$a ok $b bmc $g 1391436 $s 1050431
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 17 $c 1 $d 145 $e 20181121 $i 1475-2840 $m Cardiovascular diabetology $n Cardiovasc Diabetol $x MED00008211
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace